PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients

Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells in the bone marrow. MM results in diffuse or focal bone infiltration and extramedullary lesions. Over the past two decades, advances have been made with regard to the diagnosis, stag...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailly, Clément, Leforestier, Rodolphe, Jamet, Bastien, Carlier, Thomas, Bourgeois, Mickael, Guérard, François, Touzeau, Cyrille, Moreau, Philippe, Chérel, Michel, Kraeber-Bodéré, Françoise, Bodet-Milin, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343979/
https://www.ncbi.nlm.nih.gov/pubmed/28218709
http://dx.doi.org/10.3390/ijms18020445
Descripción
Sumario:Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malignant plasma cells in the bone marrow. MM results in diffuse or focal bone infiltration and extramedullary lesions. Over the past two decades, advances have been made with regard to the diagnosis, staging, treatment, and imaging of MM. Computed tomography (CT) and magnetic resonance imaging (MRI) are currently recommended as the most effective imaging modalities at diagnostic. Yet, recent data from the literature suggest that positron emission tomography combined with computed tomography (PET/CT) using (18)F-deoxyglucose (FDG) is a promising technique for initial staging and therapeutic monitoring in this pathology. This paper reviews the recent advances as well as the potential place of a more specific radiopharmaceutical in MM.

Ejemplares similares